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Abstract
Translational medicine depends on a rapid and efficient exchange of results between the bench and the bedside.
A recent example from the field of cancer immunotherapy highlights the essential nature of this exchange.
Methods have been developed to convert a patient’s cytotoxic T cells into efficient and specific killers of cancer
cells in patients with leukemia. By using recombinant DNA techniques, a lentiviral vector was constructed to
express chimeric antigen receptors in cytotoxic T cells from patients with advanced chronic lymphocytic leukemia.
The purpose of the chimeric receptors was to direct the cytotoxic T cell activity against cells causing the cancer.
The effect of infusing the engineered T cells back into the cancer patients was tested in a Phase I trial at the
University of Pennsylvania, and the initial results were described in two articles from the research team of Dr. Carl
June. The remarkable success of this trial should energize further applications of biotechnology in the development
of new cancer immunotherapies.
Main Text
Recent advances in cancer immunotherapy have allowed
the conversion of T cells from leukemia patients into
efficient and specific killers of their own cancer cells.
The new technique has been recently tested with
remarkable results. The outward signs of the successful
t h e r a p yw e r ed r a m a t i ca n dc l e a r .T h ec a n c e rp a t i e n t s
shook with fever, chills and pain; their blood pressure
precipitously dropped. They drifted in and out of sleep
for days following the infusion of their own engineered
killer T cells. The internal struggle peaked between two
and three weeks after T cell reinfusion. The load of
lysed cancer cells stressed and nearly poisoned the
patients’ kidneys. Their immune systems, reinvigorated
by the immunotherapy, had destroyed nearly 1 kg of
cancer cells. No other available treatment could have
achieved a comparable therapeutic success. The new
treatment, administered by Dr. Carl June and his collea-
gues of the Abrahamson Cancer Center at the Univer-
sity of Pennsylvania, achieved an unprecedented
complete eradication of the cancer in two of the three
chronic lymphocytic leukemia (CLL) patients in whom
it was tried. It had been a dream of many: the
harnessing of the immune system’sf e r o c i o u sp o w e rt o
eliminate an advanced metastatic cancer.
The stunning results were published in two simulta-
neous journal articles [1,2], one of the reports present-
ing data from a single patient [1]. The success was
beyond expectation. This, after all, was a Phase I clinical
trial, one in which the primary objective was to test dif-
ferent doses of the engineered cytotoxic lymphocytes
(CTL). Technically, the success could be traced to the
fusion of extracellular and intracellular domains into a
new, synthetic receptor for the CD8+ T cells [3]. In
immunotherapy jargon, this type of recombinant protein
is called a chimeric antigen receptor (CAR). In this case,
the extracellular domain was derived from a mouse
monoclonal antibody specific for the CD19 surface pro-
tein of human B cells. Because CLL is a B cell cancer,
CLL cells express CD19. The anti-CD19 antibody was
reduced to its smallest active form, a single-chain vari-
able fragment (scFv), and grafted onto a T cell receptor
transmembrane domain. On the inside of the cell, the
construct was fused to the cytoplasmic signaling
domains of CD137 (41BB) and the ζ chain of CD3 (Fig-
ure 1). This particular combination of functional
domains is credited for achieving the spectacular success
of the therapy.
T h eg e n ef o rt h i sC A Rw a sd e l i v e r e db yl e n t i v i r u st o
purified cytotoxic killer T cells from each patient. The
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of the lentivirus vector. The choice of this virus proved
fortunate because the natural host for HIV-1 is a T lym-
phocyte. Therefore, the vector included sequences that
had evolved for replication and expression in T cells. A
previous version of this vector was used to treat patients
with chronic HIV infections [4]. The CLL patients’ puri-
fied T cells were transduced in vitro, then stored for the
time required to treat each patient with chemotherapy
and reduce the numbers of unmodified lymphocytes.
This provided the in vivo space to accommodate the
engineered T cells.
Once the patients were ready for the experimental
treatment, they received between 15 Million and 1 Bil-
lion transduced CTL. The CTL rapidly multiplied to
approximately 1000-fold higher numbers in vivo [2].
Part of this expansion may be attributed to the presence
of target cells. The scientists performing the trial esti-
mated that each engineered CTL destroyed nearly 1000
leukemia cells, until, three weeks after the infusion of
Figure 1 The biotechnology of chimeric antigen receptors for cytotoxic T cell-based cancer immunotherapy. A. Map of pELPS 19-BB-3ζ,
a lentiviral vector that was approved for clinical trials [1]. The open reading frame encoding the chimeric fusion protein CD19-BBζ contains
portions coding for an anti-CD19 single-chain variable region fragment (scFv), the hinge and transmembrane (TM) domain of CD8, and a pair of
signaling endodomains (one from CD137, the other from CD3ζ). This fusion protein gene is embedded within a disabled HIV-derived backbone
containing truncated gag, pol and env sequences and the 5’ and 3’ long terminal repeats (LTR). In addition, the construct contains elongation
factor 1a (EF-1a) coding sequences, the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and the bovine growth
hormone polyadenylation (GH poly A) tail, as well as the ampicillin resistance gene and a bacterial replication origin. The total size of the
construct is 11,556 base pairs. B. Diagram of the chimeric receptor protein in the T cell plasma membrane. The extracellular antibody recognition
domain is linked via the CD8 TM domain to the cytoplasmic signaling domains of CD137 and CD3ζ. These endodomains accomplish the
activation of transduced T cells and they stimulate T cell survival and proliferation in vivo.
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of CTL proliferation corresponded to the highest level
of IFN-g, IL-6 and CXCL9 in circulation [2]. These cyto-
kines were responsible for the patients’ high fever. Once
the CLL numbers dropped below detection levels, the
CTL numbers normalized and the remaining engineered
cells acquired the phenotype of effector and memory T
cells. At that time, the patients’ overall wellbeing mark-
edly improved.
One side-effect of the therapy is B cell immunodefi-
ciency because the engineered CTL also kill the patients’
non-cancerous B cells. This was an anticipated conse-
quence of the therapy because the CTL target antigen,
the CD19 receptor, is expressed on all mature B cells
and B cell precursors. The transfer of IgG from normal
donors (IVIG) can replenish the patients’ circulating
antibodies and partially compensate for the absence of B
cells. The IgG injections will be performed at monthly
intervals to reduce the risk of infections in treated
patients. Two of the patients were, at the time of the
reports, free of cancer recurrence for 6 to 11 months
[2]. The third showed a sustained improvement of the
CLL.
Various groups of scientists had attempted to modify
CTL to attack cancer cells. In pioneering work, Eshhar
and collaborators from the Weizmann Institute of
Science in Rehovot (Israel) demonstrated that CTL can
express a recombinant surface receptor that links an
extracellular recognition domain derived from an anti-
body to an intracellular signaling domain derived from
the T cell receptor [5]. Such T cells no longer depend
on recognition of HLA-peptide complexes for specific
signaling and T cell activation.
Normally, cytotoxic T cells recognize foreign peptides
in the groove of an HLA class I receptor. The peptides
may be derived from a virus infecting a host cell, which
degrades a portion of the newly forming viral proteins
into peptides and loads them into a class I HLA. The
recognition of the peptides as foreign to the host trig-
gers the T cell to release perforin and granzyme, pro-
teins that form pores in the target cell and initiate a
cascade of enzymatic reactions leading to the pro-
grammed death of the infected cells. In this manner, the
virus is purged from the body.
An analogous reaction is thought to occur between
cytotoxic T cells and tumor cells. The oncogenic trans-
formation of a cancer cell induces the expression of
proteins that are not expressed in healthy tissues. The
immune system can detect the differences in HLA-
associated peptides from cancer cells, and the cytotoxic
T cells, in consequence, release their cell-degrading
effector molecules. However, in advanced cancers,
these cytotoxic T cells are depleted and inefficient.
Gradually, the cancer cells gain the upper hand and
grow to numbers that become more and more difficult
to control.
In T cells expressing chimeric antigen receptors, the
scFv antibody fragment that binds to antigen substitutes
for the TCR binding to HLA plus peptide. The initial
success of Gross et al. [5] inspired numerous subsequent
studies but obstacles hindered efforts to express recom-
binant receptors that could bind the desired targets and
activate the cytolytic functions of the T cells [6]. Various
investigators designed and tested second and third gen-
eration CAR fusion proteins because single activation
domain CAR showed only limited utility for the stimula-
tion of naïve T cells [6]. The more advanced receptor
design incorporated additional endodomains that could
simultaneously activate more than one signaling path-
way. Experiments by Imai et al. [7] and Finney et al. [8]
tested dual activation domains, including the combina-
tion of CD3 and CD137 (4-1BB) and found the added
activation domains to increase responses of engineered
CTL. Subsequently, Milone et al. [3] demonstrated the
in vivo efficacy of the new chimeric activation domains
in xenogeneic tumor bearing mice. These experiments
set the stage for the successful clinical trial at the Uni-
versity of Pennsylvania [1,2].
The breakthrough occurred with the discovery that
the cytoplasmic domain from CD137 (4-1BB) enabled
strong activation of the engineered T cells, provided
that it was inserted between the CD8a transmembrane
region and the CD3ζ cytoplasmic domain [3]. This tan-
dem configuration of activating domains merged into a
single polypeptide chain the task of delivering two sig-
nals needed for the activation of naïve T cells (Figure 1).
In this manner, binding of the extracellular antibody
domain to antigen could transmit two signals needed to
induce the maturation of naïve CD8 T cells into effector
T cells. The cells expressing the tandem chimeric anti-
gen receptors received strong signals to proliferate and
differentiate into potent cancer-destroying killer T cells
[1].
Clearly, the new research will stimulate efforts to
extend this approach to other refractory cancers. Still,
caveats remain. The numbers of patients treated up to
now remain very small and the time elapsed since the
treatment is short, thus success could still remain elu-
s i v e .H o w e v e r ,h o p e st h a tap r o m i s i n gn e wt h e r a p yi s
within reach increase with every passing day. In all,
more than 25 clinical trials currently explore the use of
chimeric T cell receptors in various forms of cancer [9].
I tm i g h tb ef e a s i b l et oe x t e n dt h eC L Lt h e r a p y[ 1 , 2 ]t o
other B lymphocytic neoplasms, as similarly engineered
CTL should be capable of attacking any CD19-positive
cancer cells. Yet important hurdles remain: It may prove
difficult to develop antibodies with exclusive specificity
for cancer cells that do not cross-react with healthy
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that could damage vital organs. Furthermore, the violent
side-effects associated with the clearance of cancer cells
make it desirable to find ways to regulate the rate of
CTL activation. For example, there are ways in which a
“safety switch” may be incorporated into engineered T
cells that could deactivate them in case that the CTL
therapy exposes patients to unacceptable complications
[10]. The success of the phase I trial with tandem endo-
domain CARs delivered by lentivirus [1.2] will surely
energize the search for additional recombinant immune
therapies for advanced cancer.
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